191 related articles for article (PubMed ID: 15590241)
1. Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials.
Sturmey P
Res Dev Disabil; 2005; 26(1):87-97. PubMed ID: 15590241
[TBL] [Abstract][Full Text] [Related]
2. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.
Sandler AD; Sutton KA; DeWeese J; Girardi MA; Sheppard V; Bodfish JW
N Engl J Med; 1999 Dec; 341(24):1801-6. PubMed ID: 10588965
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of transdermal secretin on behavior of children with autism.
Ratliff-Schaub K; Carey T; Reeves GD; Rogers MA
Autism; 2005 Jul; 9(3):256-65. PubMed ID: 15937041
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism.
Coniglio SJ; Lewis JD; Lang C; Burns TG; Subhani-Siddique R; Weintraub A; Schub H; Holden EW
J Pediatr; 2001 May; 138(5):649-55. PubMed ID: 11343038
[TBL] [Abstract][Full Text] [Related]
5. Role of risperidone in children with autism spectrum disorder.
Chavez B; Chavez-Brown M; Rey JA
Ann Pharmacother; 2006 May; 40(5):909-16. PubMed ID: 16684811
[TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
7. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism.
Owley T; McMahon W; Cook EH; Laulhere T; South M; Mays LZ; Shernoff ES; Lainhart J; Modahl CB; Corsello C; Ozonoff S; Risi S; Lord C; Leventhal BL; Filipek PA
J Am Acad Child Adolesc Psychiatry; 2001 Nov; 40(11):1293-9. PubMed ID: 11699803
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of porcine secretin in children with autism and pervasive developmental disorder.
Kern JK; Van Miller S; Evans PA; Trivedi MH
J Autism Dev Disord; 2002 Jun; 32(3):153-60. PubMed ID: 12108616
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study.
Lightdale JR; Hayer C; Duer A; Lind-White C; Jenkins S; Siegel B; Elliott GR; Heyman MB
Pediatrics; 2001 Nov; 108(5):E90. PubMed ID: 11694674
[TBL] [Abstract][Full Text] [Related]
10. Improved social and language skills after secretin administration in patients with autistic spectrum disorders.
Horvath K; Stefanatos G; Sokolski KN; Wachtel R; Nabors L; Tildon JT
J Assoc Acad Minor Phys; 1998; 9(1):9-15. PubMed ID: 9585670
[TBL] [Abstract][Full Text] [Related]
11. Modeling clinical outcome of children with autistic spectrum disorders.
Coplan J; Jawad AF
Pediatrics; 2005 Jul; 116(1):117-22. PubMed ID: 15995041
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological treatment options for autism spectrum disorders in children and adolescents.
Leskovec TJ; Rowles BM; Findling RL
Harv Rev Psychiatry; 2008; 16(2):97-112. PubMed ID: 18415882
[TBL] [Abstract][Full Text] [Related]
13. Use of atypical antipsychotics in the treatment of autistic disorder.
Stachnik JM; Nunn-Thompson C
Ann Pharmacother; 2007 Apr; 41(4):626-34. PubMed ID: 17389666
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders.
Findling RL
J Clin Psychiatry; 2005; 66 Suppl 10():26-31. PubMed ID: 16401147
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism.
Corbett B; Khan K; Czapansky-Beilman D; Brady N; Dropik P; Goldman DZ; Delaney K; Sharp H; Mueller I; Shapiro E; Ziegler R
Clin Pediatr (Phila); 2001 Jun; 40(6):327-31. PubMed ID: 11824175
[TBL] [Abstract][Full Text] [Related]
16. Secretin treatment for autism.
Rimland B
N Engl J Med; 2000 Apr; 342(16):1216-7; author reply 1218. PubMed ID: 10777377
[No Abstract] [Full Text] [Related]
17. Regression of language and non-language skills in pervasive developmental disorders.
Meilleur AA; Fombonne E
J Intellect Disabil Res; 2009 Feb; 53(2):115-24. PubMed ID: 19054269
[TBL] [Abstract][Full Text] [Related]
18. Use of secretin in the treatment of childhood autism.
Kamińska B; Czaja M; Kozielska E; Mazur E; Korzon M
Med Sci Monit; 2002 Jan; 8(1):RA22-6. PubMed ID: 11782669
[TBL] [Abstract][Full Text] [Related]
19. Lack of benefit of intravenous synthetic human secretin in the treatment of autism.
Molloy CA; Manning-Courtney P; Swayne S; Bean J; Brown JM; Murray DS; Kinsman AM; Brasington M; Ulrich CD
J Autism Dev Disord; 2002 Dec; 32(6):545-51. PubMed ID: 12553591
[TBL] [Abstract][Full Text] [Related]
20. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
Chez MG; Aimonovitch M; Buchanan T; Mrazek S; Tremb RJ
J Child Neurol; 2004 Mar; 19(3):165-9. PubMed ID: 15119476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
